Key Details
Price
$70.00Annual Revenue
$305.21 MAnnual EPS
-$5.34Annual ROE
225.83%Beta
0.99Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 03, 2011Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
BRIDGEWATER, N.J., Jan. 2, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on prioritizing patients, has announced that its management team will speak at the 43rd Annual J.P.
We have just put together a list of the 12 Best Multibagger Stocks to Invest in at the moment. In this article, we will examine how Insmed Incorporated (NASDAQ:INSM) compares to the other multibagger stocks. The US stock market has been rising in 2024, helping the S&P 500 reach new record levels.
BRIDGEWATER, N.J., Dec. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on putting people first, has announced that it has given inducement awards to 30 new employees. The company aims to provide top-quality therapies to improve the lives of patients with serious illnesses.
Insmed Incorporated's ARIKAYCE, which is approved for MAC lung disease, saw significant revenue growth in the third quarter of 2024 and may receive expanded FDA approval, increasing its market potential. The company plans to file a New Drug Application for Brensocatib for bronchiectasis in the fourth quarter of 2024, with a possible U.S. launch by mid-2025. Additionally, results from a phase 2b study using TPIP for treating patients with PAH are anticipated in the second half of 2025.
On November 6, 2024, Insmed Incorporated, a biopharmaceutical company focused on improving patient lives, announced that its management will speak at upcoming investor conferences. They will present at Guggenheim's Inaugural Healthcare Innovation Conference in Boston on November 11, 2024, at 1:00 p.m.
Examine how Insmed's (INSM) international revenue results influence Wall Street financial analysts' forecasts and the stock's future outlook. This analysis will help understand the company's performance and its potential impact on investors.
INSM reported a larger loss in the third quarter than anticipated. The company intends to meet with the FDA before the end of 2024 to talk about the chance of getting faster approval to broaden the use of Arikayce.
Insmed Incorporated (NASDAQ:INSM) will hold its Q3 2024 Earnings Conference Call on October 31, 2024, at 8:00 AM ET. The call will feature key company participants, including Bryan Dunn, Will Lewis, Sara Bonstein, and Martina Flammer. Various conference call participants from different financial institutions will also be present.
Insmed (INSM) reported a quarterly loss of $1.27 per share, which is worse than the Zacks Consensus Estimate of a $1.19 loss. This is also a decline compared to a loss of $1.10 per share from the same period last year.
Insmed Incorporated announced that ARIKAYCE® generated $93.4 million in revenue for the third quarter of 2024, marking an 18% increase compared to the same period in 2023. The company is on track to submit a New Drug Application for Brensocatib in bronchiectasis by the end of 2024, with a potential U.S. launch expected in mid-2025. Additionally, Insmed has a strong financial position, ending the quarter with around $1.5 billion in cash and equivalents, and has renegotiated a term loan to lower costs and secure an extra $150 million.
FAQ
- What is the primary business of Insmed Incorporated?
- What is the ticker symbol for Insmed Incorporated?
- Does Insmed Incorporated pay dividends?
- What sector is Insmed Incorporated in?
- What industry is Insmed Incorporated in?
- What country is Insmed Incorporated based in?
- When did Insmed Incorporated go public?
- Is Insmed Incorporated in the S&P 500?
- Is Insmed Incorporated in the NASDAQ 100?
- Is Insmed Incorporated in the Dow Jones?
- When was Insmed Incorporated's last earnings report?
- When does Insmed Incorporated report earnings?
- Should I buy Insmed Incorporated stock now?